By looking at the electrical activity of tumor cells, rather than the neurons that innervate them, investigators at Baylor College of Medicine have added both basic and translational insights to the emerging field of cancer neuroscience. In their studies, which were published in Cancer Cell on Sept. 5, 2024, the researchers identified the cell of origin for IDH-mutated gliomas. Read More
Candid Therapeutics Inc. launched with ex-China control of two bispecific T-cell engager antibodies that it plans to develop for autoimmune diseases. The San Diego-based company will start off with a pocketful of cash, having raised over $370 million for the development of the in-licensed candidates. Read More
Integrated Nanotherapeutics Inc. has received an award from Breakthrough T1D (formerly Juvenile Diabetes Research Foundation Ltd. [JDRF]) to advance the company’s technology to induce immune tolerance in type 1 diabetes. Read More
The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer. Read More
Researchers from Chroma Medicine Inc. presented preclinical data for the novel PCSK9-targeted epigenetic editor (PCSK9-EE) being developed as cardiovascular therapy for the reduction of low-density lipoprotein cholesterol. Read More
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases. Read More
Orsobio Inc. has closed an oversubscribed $67 million series B financing, the proceeds of which will be used to accelerate development of its mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders. Read More
A Scandiedge Therapeutics AB patent details compounds targeting pyruvate kinase PKLR reported to be useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma. Read More
IRCCS San Raffaele, Universita Degli Studi Di Perugia and Universita Vita-Salute San Raffaele have jointly developed new oxysterols receptor LXR-α (NR1H3; LXRA) and/or LXR-β (NR1H2; LXRB) antagonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders. Read More
Cancer immunotherapy based on programmed death 1 ligand 1 (PD-L1) has made huge steps toward overcoming cancer, but many patients still experience poor response to anti-PD-L1 therapy or do not have a durable response. Read More
New miR-124 activators have been reported in a recent Nanjing Synnocare Pharmaceutical Technology Co. Ltd. patent as potentially useful for the treatment of Alzheimer type dementia, Parkinson’s disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, cancer and viral infections. Read More
Cascade Pharmaceuticals Inc. has disclosed new thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), hypothyroidism, atherosclerosis and dyslipidemia. Read More
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis due to rapid growth, early metastases and acquired drug resistance, making it difficult to manage. Read More
